CODEXIS, INC.
StreetZero Signal 48
About CODEXIS, INC.
Codexis, Inc. is a public biotechnology company founded in 2002 and headquartered in Redwood City, CA. It specializes in protein engineering and provides enzymatic solutions for efficient manufacturing of complex oligonucleotide therapeutics and other products. The company operates a B2B model and is listed on NASDAQ under ticker CDXS. It has raised over $252 million across multiple rounds since inception.
LATEST FUNDINGRule 144
$12K
Announced 2026-11-16
TOTAL RAISED$252.40M
IN THE NEWS
- ๐ Codexis, Inc.
- ๐ Codexis Announces Pricing of Public Offering of Common Stock :: Codexis, Inc. (CDXS)
- ๐ Codexis Announces Proposed Public Offering of Common Stock :: Codexis, Inc. (CDXS)
- ๐ Codexis - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ Codexis Stock Price Today NASDAQ CDXS - Investing.com Canada
EMPLOYEESโ
FOUNDED2002
HQRedwood City, CA, United States
Industry
Public Equity (NASDAQ)
Tags
B2BBiotechnologyPublicProtein Engineering
Investors
Key highlights
- Completed multiple public equity offerings including a 2020 underwritten offering of common stock.
- Secured $60M term loan facility with Trinity Capital in November 2026.
- Focuses on ECO Synthesis platform for stereo-defined siRNA manufacturing.
- Total historical funding exceeds $252 million from institutional and strategic investors.
Ask StreetZero about CODEXIS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account